Y-Biologics, Inc. operates as a biopharmaceutical company, which engages in the research and development of antibody therapeutics. The firm’s products include Ymax ABL, a human antibody library and ALiCE, a novel format for bispecific T-cell engager antibodies. The company was founded on December 31, 2007 and is headquartered in Daejeon, South Korea.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company